Aileron Therapeutics, Inc.

As of September 30, 2024, Aileron Therapeutics, Inc. has 21.67M shares outstanding.

These figures are as of September 30, 2024.

As of September 30, 2024, Aileron Therapeutics, Inc. maintains a current ratio of 3.30, meaning it holds 3.3x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended September 30, 2024. Return on assets (ROA) is negative at -49.97, reflecting losses generated across the asset base.

As of the close on February 7, 2025, Aileron Therapeutics, Inc.'s stock has declined approximately 54.14% over the past 52 weeks. The 50-day moving average sits at 2.19, while the 200-day moving average is 2.94.

These figures cover the twelve months ended September 30, 2024. Free cash flow yield is negative at -47.35: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -26.08, meaning Aileron Therapeutics, Inc. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Aileron Therapeutics, Inc.'s most recent stock split took place on November 11, 2022 with a 20:1 split ratio.

As of September 30, 2024, Aileron Therapeutics, Inc. has an Altman Z-Score of -27.00, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.